Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022.

• Earlier, the data were anticipated in Q1 of 2022.

• The study enrolled more than 400 patients across 30 sites in Europe, Israel, and Canada.

• Piclidenoson is an A3 adenosine receptor agonist (A3AR) small molecule that inhibits interleukin-17 and interleukin-23, both pivotal for the formation of skin lesions.

• Piclidenoson has also recently been shown to induce the death of pathological skin cells.

• The Comfort study's primary endpoint is the proportion of patients who achieve a PASI score response of ≥75% (PASI 75) vs. placebo at week 16. Secondary endpoints include non-inferiority to Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast).

• Also See: Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient.

• Price Action: CANF shares are down 7.21% at $1.03 during the premarket session on the last check Tuesday.

See more from Benzinga

• EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders

• Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.